Cargando…

Effects of Pregabalin on Central Sensitization in Patients with Chronic Pancreatitis in a Randomized, Controlled Trial

BACKGROUND: Intense abdominal pain is the dominant feature of chronic pancreatitis. During the disease changes in central pain processing, e.g. central sensitization manifest as spreading hyperalgesia, can result from ongoing nociceptive input. The aim of the present study is to evaluate the effect...

Descripción completa

Detalles Bibliográficos
Autores principales: Bouwense, Stefan A. W., Olesen, Søren S., Drewes, Asbjørn M., Poley, Jan-Werner, van Goor, Harry, Wilder-Smith, Oliver H. G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412837/
https://www.ncbi.nlm.nih.gov/pubmed/22879908
http://dx.doi.org/10.1371/journal.pone.0042096
_version_ 1782240001163001856
author Bouwense, Stefan A. W.
Olesen, Søren S.
Drewes, Asbjørn M.
Poley, Jan-Werner
van Goor, Harry
Wilder-Smith, Oliver H. G.
author_facet Bouwense, Stefan A. W.
Olesen, Søren S.
Drewes, Asbjørn M.
Poley, Jan-Werner
van Goor, Harry
Wilder-Smith, Oliver H. G.
author_sort Bouwense, Stefan A. W.
collection PubMed
description BACKGROUND: Intense abdominal pain is the dominant feature of chronic pancreatitis. During the disease changes in central pain processing, e.g. central sensitization manifest as spreading hyperalgesia, can result from ongoing nociceptive input. The aim of the present study is to evaluate the effect of pregabalin on pain processing in chronic pancreatitis as assessed by quantitative sensory testing (QST). METHODS: This randomized, double-blind, placebo-controlled trial evaluated effects of pregabalin on pain processing. QST was used to quantify pain processing by measuring thresholds to painful electrical and pressure stimulation in six body dermatomes. Descending endogenous pain modulation was quantified using the conditioned pain modulation (CPM) paradigm to elicit a DNIC (diffuse noxious inhibitory controls) response. The main effect parameter was the change in the sum of all body pain threshold values after three weeks of study treatment versus baseline values between both treatment groups. RESULTS: 64 patients were analyzed. No differences in change in sum of pain thresholds were present for pregabalin vs. placebo after three weeks of treatment. For individual dermatomes, change vs. baseline pain thresholds was significantly greater in pregabalin vs. placebo patients for electric pain detection threshold in C5 (P = 0.005), electric pain tolerance threshold in C5 (P = 0.04) and L1 (P = 0.05), and pressure pain tolerance threshold in T4 (P = 0.004). No differences were observed between pregabalin and placebo regarding conditioned pain modulation. CONCLUSION: Our study provides first evidence that pregabalin has moderate inhibitory effects on central sensitization manifest as spreading hyperalgesia in chronic pancreatitis patients. These findings suggest that QST can be of clinical use for monitoring pain treatments in the context of chronic pain. TRIAL REGISTRATION: ClinicalTrials.gov NCT00755573
format Online
Article
Text
id pubmed-3412837
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-34128372012-08-09 Effects of Pregabalin on Central Sensitization in Patients with Chronic Pancreatitis in a Randomized, Controlled Trial Bouwense, Stefan A. W. Olesen, Søren S. Drewes, Asbjørn M. Poley, Jan-Werner van Goor, Harry Wilder-Smith, Oliver H. G. PLoS One Research Article BACKGROUND: Intense abdominal pain is the dominant feature of chronic pancreatitis. During the disease changes in central pain processing, e.g. central sensitization manifest as spreading hyperalgesia, can result from ongoing nociceptive input. The aim of the present study is to evaluate the effect of pregabalin on pain processing in chronic pancreatitis as assessed by quantitative sensory testing (QST). METHODS: This randomized, double-blind, placebo-controlled trial evaluated effects of pregabalin on pain processing. QST was used to quantify pain processing by measuring thresholds to painful electrical and pressure stimulation in six body dermatomes. Descending endogenous pain modulation was quantified using the conditioned pain modulation (CPM) paradigm to elicit a DNIC (diffuse noxious inhibitory controls) response. The main effect parameter was the change in the sum of all body pain threshold values after three weeks of study treatment versus baseline values between both treatment groups. RESULTS: 64 patients were analyzed. No differences in change in sum of pain thresholds were present for pregabalin vs. placebo after three weeks of treatment. For individual dermatomes, change vs. baseline pain thresholds was significantly greater in pregabalin vs. placebo patients for electric pain detection threshold in C5 (P = 0.005), electric pain tolerance threshold in C5 (P = 0.04) and L1 (P = 0.05), and pressure pain tolerance threshold in T4 (P = 0.004). No differences were observed between pregabalin and placebo regarding conditioned pain modulation. CONCLUSION: Our study provides first evidence that pregabalin has moderate inhibitory effects on central sensitization manifest as spreading hyperalgesia in chronic pancreatitis patients. These findings suggest that QST can be of clinical use for monitoring pain treatments in the context of chronic pain. TRIAL REGISTRATION: ClinicalTrials.gov NCT00755573 Public Library of Science 2012-08-06 /pmc/articles/PMC3412837/ /pubmed/22879908 http://dx.doi.org/10.1371/journal.pone.0042096 Text en © 2012 Bouwense et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Bouwense, Stefan A. W.
Olesen, Søren S.
Drewes, Asbjørn M.
Poley, Jan-Werner
van Goor, Harry
Wilder-Smith, Oliver H. G.
Effects of Pregabalin on Central Sensitization in Patients with Chronic Pancreatitis in a Randomized, Controlled Trial
title Effects of Pregabalin on Central Sensitization in Patients with Chronic Pancreatitis in a Randomized, Controlled Trial
title_full Effects of Pregabalin on Central Sensitization in Patients with Chronic Pancreatitis in a Randomized, Controlled Trial
title_fullStr Effects of Pregabalin on Central Sensitization in Patients with Chronic Pancreatitis in a Randomized, Controlled Trial
title_full_unstemmed Effects of Pregabalin on Central Sensitization in Patients with Chronic Pancreatitis in a Randomized, Controlled Trial
title_short Effects of Pregabalin on Central Sensitization in Patients with Chronic Pancreatitis in a Randomized, Controlled Trial
title_sort effects of pregabalin on central sensitization in patients with chronic pancreatitis in a randomized, controlled trial
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3412837/
https://www.ncbi.nlm.nih.gov/pubmed/22879908
http://dx.doi.org/10.1371/journal.pone.0042096
work_keys_str_mv AT bouwensestefanaw effectsofpregabalinoncentralsensitizationinpatientswithchronicpancreatitisinarandomizedcontrolledtrial
AT olesensørens effectsofpregabalinoncentralsensitizationinpatientswithchronicpancreatitisinarandomizedcontrolledtrial
AT drewesasbjørnm effectsofpregabalinoncentralsensitizationinpatientswithchronicpancreatitisinarandomizedcontrolledtrial
AT poleyjanwerner effectsofpregabalinoncentralsensitizationinpatientswithchronicpancreatitisinarandomizedcontrolledtrial
AT vangoorharry effectsofpregabalinoncentralsensitizationinpatientswithchronicpancreatitisinarandomizedcontrolledtrial
AT wildersmitholiverhg effectsofpregabalinoncentralsensitizationinpatientswithchronicpancreatitisinarandomizedcontrolledtrial